Liquidia (NASDAQ:LQDA) Posts Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Liquidia (NASDAQ:LQDA) announced its earnings results on Wednesday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.07), Zacks reports. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%.

Liquidia Price Performance

Shares of Liquidia stock opened at $14.92 on Thursday. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $16.99. The firm has a market capitalization of $1.26 billion, a P/E ratio of -9.15 and a beta of 0.07. The company’s 50 day moving average price is $14.67 and its two-hundred day moving average price is $12.12.

Insider Buying and Selling at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 16,393 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $193,109.54. Following the sale, the general counsel now owns 573,478 shares in the company, valued at $6,755,570.84. This trade represents a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Rajeev Saggar sold 6,249 shares of Liquidia stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $73,613.22. Following the transaction, the insider now owns 270,388 shares in the company, valued at approximately $3,185,170.64. This trade represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock worth $843,326 over the last quarter. Corporate insiders own 30.10% of the company’s stock.

Analyst Upgrades and Downgrades

LQDA has been the topic of several analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. Wells Fargo & Company initiated coverage on shares of Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $25.38.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).